2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 579

Methotrexate Does Not Influence 1-Year Bone Mineral Density in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 473

Methotrexate, Blood Pressure and Arterial Wave Reflection in Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 541

Microrna-125b Expression in PBMCs Is Associated with Disease Activity in Patients with Early Rheumatoid Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 23

Microvesicle-Associated Hsa-Mir-223-3p Is Elevated in Rheumatoid Synovial Fluid Compared with Osteoarthritis Synovial Fluid

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 749

Microvesicles Containing Nucleic Acids and Expressing Immunoglobulins and HMGB1 Are Abundant in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 303

Mining RNA-Seq of Peripheral Blood Mononuclear Cells from JDM Alone Compared with JDM Plus Psoriasis for Biomarkers of Disease Activity

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 682

Misalignment Between Physician and Patient Satisfaction with Current Psoriatic Arthritis Treatment

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 278

Mitral Valve Prolapse in Patients with Joint Hypermobility Syndrome

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 205

Mode of Action of Therapeutic Anti-Citrullinated Protein Antibodies Revealed: Inflammation Reduction Due to Inhibition of Netosis

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 845

Modelling of Longitudinal Changes in Lung Function in Patients with Systemic Sclerosis and Their Association with Development of Pulmonary Hypertension

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 605

Monitoring of Epstein Barr Virus, Cytomegalovirus and Varicella Zooster Virus Load in Patients Receiving Tocilizumab for Rheumatoid Arthritis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 422

Mood Disorder Is Highly Prevalent in a Multi-Ethnic Urban Pediatric Lupus Cohort

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 339

More Inflammatory Signs on Ultrasound, Severe Pain and Stiffness Are Associated with Erosive Than Non-Erosive Hand Osteoarthritis

Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

9:00AM-11:00AM: Abstract Number: 60

Mortality of Systemic Lupus Erythematosus in Puerto Rico Assessed By Multiple-Cause-of-Death Analysis

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 465

MRI Bone Erosion at Baseline Predicts the Subsequent Radiographic Progression in Early-Stage RA Patients Who Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort

Rheumatoid Arthritis - Clinical Aspects Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].